Bixiye
QP28-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit ( QL) Criteria: OpzeluraTM (ruxolitnib)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2022
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1971 - 1980 ee natiijooyinka 3167
Bixiye
QP29-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: TavneosTM (avacopan)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2022
Bixiye
QP30-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: TyrvayaTM (varenicline)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 13, 2022
Bixiye
P20-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates — Effective June 6, 2022
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P21-22 Medical Drug Management Update – Infliximab Prior Authorization and Preferred Product Expansion to Include Unbranded Infliximab
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P22-22 eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P17-22 Updated Minnesota Health Care Programs and Minnesota Senior Health Options Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P18-22 Non-Covered Procedure Codes for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
P19-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022
Bixiye
2022 April Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2022